The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer’s disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate &a...
Main Authors: | Yuriko Nakaoku, Satoshi Saito, Yumi Yamamoto, Takakuni Maki, Ryosuke Takahashi, Masafumi Ihara |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/10/2539 |
Similar Items
-
Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al. -
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
by: Shen-Chih Wang, et al.
Published: (2022-03-01) -
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01) -
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
by: Ikuko Shibasaki, et al.
Published: (2022-07-01) -
Identification and Characterization of Dipeptidyl Peptidase-IV Inhibitory Peptides from Oat Proteins
by: Wei Wang, et al.
Published: (2022-05-01)